KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Equity Average (2016 - 2026)

Boston Scientific's Equity Average history spans 18 years, with the latest figure at $25.2 billion for Q1 2026.

  • On a quarterly basis, Equity Average rose 13.84% to $25.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $25.2 billion, a 13.84% increase, with the full-year FY2025 number at $23.0 billion, up 11.39% from a year prior.
  • Equity Average hit $25.2 billion in Q1 2026 for Boston Scientific, up from $23.9 billion in the prior quarter.
  • Over the last five years, Equity Average for BSX hit a ceiling of $25.2 billion in Q1 2026 and a floor of $62.5 million in Q2 2024.
  • Historically, Equity Average has averaged $13.9 billion across 5 years, with a median of $10.9 billion in 2025.
  • The widest YoY moves for Equity Average: up 17408.8% in 2025, down 9.26% in 2025.
  • Tracing BSX's Equity Average over 5 years: stood at $8.4 billion in 2022, then skyrocketed by 128.89% to $19.3 billion in 2023, then rose by 10.52% to $21.4 billion in 2024, then increased by 12.02% to $23.9 billion in 2025, then grew by 5.17% to $25.2 billion in 2026.
  • Business Quant data shows Equity Average for BSX at $25.2 billion in Q1 2026, $23.9 billion in Q4 2025, and $11.5 billion in Q3 2025.